Moxonidine-SZ, 0.2 mg 28 pcs.

Hypertension (high blood pressure)

Arterial hypertension.

Indications

Arterial hypertension.

Pharmacological effect

Pharmacotherapeutic group of the drug:

Special instructions

If it is necessary to cancel beta-blockers and the drug Moxonidine taken simultaneously, first cancel the beta-blockers and only after a few days Moxonidine. There is currently no evidence that stopping Moxonidine leads to an increase in blood pressure. However, it is not recommended to stop taking Moxonidine suddenly; instead, you should gradually reduce the dose of the drug over two weeks. Avoid drinking alcohol during treatment. During treatment, regular monitoring of heart rate and electrocardiography is necessary.

Active ingredient

Moxonidine

Composition

1 film-coated tablet contains: dosage 0.2 mg:

active substance:

moxonidine 0.2 mg

excipients (core):

croscarmellose sodium (primellose) – 3.0 mg;

lactose monohydrate (lactopress) (milk sugar) -; 95.3 mg;

colloidal silicon dioxide (aerosil) -; 0.5 mg;

sodium stearyl fumarate -; 1.0 mg;

excipients (shell):

Opadry II (polyvinyl alcohol, partially hydrolyzed – 1.32 mg;

titanium dioxide E 171 -; 0.6027 mg;

talc -; 0.6 mg;

macrogol (polyethylene glycol 3350) -; 0.3705 mg;

soy lecithin E 322 -; 0.105 mg;

dye iron oxide (II) yellow -; 0.0003 mg;

dye iron oxide (II) red -; 0.0015 mg).

Description

Contraindications

– hypersensitivity to the active substance and other components of the drug;
– sick sinus syndrome;
– severe bradycardia (resting heart rate less than 50 beats/min);
– atrioventricular block II and III degrees;
– severe heart rhythm disturbances; – acute and chronic heart failure (III-IV functional class according to the NYHA classification);
– simultaneous use with tricyclic antidepressants (see section “Interaction with other drugs”);
– severe renal failure (creatinine clearance less than 30 ml/min);
– hemodialysis;
– lactation period;
– hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption;
– age over 75 years;
– age under 18 years (due to the lack of data on safety and effectiveness).

Side Effects

The frequency of side effects listed below was determined according to the following: very often (>1/10); often (>1/100, 1/1000, <1/100); including individual messages.

Interaction

Moxonidine can be prescribed with thiazide diuretics and slow calcium channel blockers. When moxonidine is used together with these and other antihypertensive drugs, the effect of moxonidine is mutually enhanced.

When prescribing moxonidine with hydrochlorothiazide, glibenclamide (glyburide) or digoxin, there is no pharmacokinetic interaction.

Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive agents.

Beta-blockers increase bradycardia and the severity of the negative ino- and dromotropic effects of moxonidine.
Moxinidine moderately enhances decreased cognitive performance in patients taking lorazepam.

Prescribing moxonidine together with benzodiazepines may be accompanied by an increase in the sedative effect of the latter.
When moxonidine is prescribed together with moclobemide, there is no pharmacodynamic interaction.

Overdose

There have been reports of several cases of non-fatal overdose when doses up to 19.6 mg were used simultaneously.

Symptoms: headache, sedation, marked decrease in blood pressure, dizziness, asthenia, bradycardia, dry oral mucosa, vomiting, fatigue, pain in the epigastric region, respiratory depression and impaired consciousness. In addition, short-term increases in blood pressure, tachycardia and hyperglycemia are also possible, as shown in several high-dose animal studies.

Treatment

There is no specific antidote. In the case of a pronounced decrease in blood pressure, it may be necessary to restore the volume of circulating blood by introducing fluid and dopamine (injection). Bradycardia can be stopped with atropine (injection). In severe cases of overdose, it is recommended to carefully monitor disturbances of consciousness and avoid respiratory depression. Alpha-adrenergic antagonists may reduce or eliminate the paradoxical hypertensive effects of moxonidine overdose. Moxonidine is excreted to a small extent during hemodialysis.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C.
Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date stated on the package.

Manufacturer

North Star NAO, Russia